US › Healthcare

Sarepta Therapeutics Inc (SRPT)

US · Healthcare · Biotechnology

$16.39+3.21%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$730.8M
Revenue YoY
-1.9%
Net profit
$331.0M
Profit YoY
+174.0%
EPS
$3.16
EPS estimate
$1.05
Net margin
45.3%

EPS came in at 3.16 against a street estimate of 1.05 — a beat of 201.0%.

Key statistics

Market cap
$1.57B
P/E
42.5
Forward P/E
5.1
P/B
1.04
Book value
$14.26
EPS (TTM)
$0.35
52-week high
$25.32
52-week low
$14.68
50-day MA
$16.94
200-day MA
$19.42
Beta
0.20

Analyst view

Analysts rate Sarepta Therapeutics Inc a buy (22 buy, 4 hold, 0 sell out of 26) with an average price target of $22.17.

Shareholding

Insiders
4.21%
Institutions
99.24%

Largest institutional holders

FundStake
BlackRock Inc13.98%
Vanguard Group Inc11.19%
Vanguard Portfolio Management, LLC6.29%
State Street Corp6.26%
AQR Capital Management LLC6.09%
Two Sigma Investments LLC4.35%
Vanguard Capital Management, LLC4.34%
First Trust Advisors L.P.3.92%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sarepta Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.